These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38805050)

  • 41.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 42. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
    Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
    JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
    Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F
    Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
    Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
    Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
    Tie J; Kinde I; Wang Y; Wong HL; Roebert J; Christie M; Tacey M; Wong R; Singh M; Karapetis CS; Desai J; Tran B; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2015 Aug; 26(8):1715-22. PubMed ID: 25851626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer.
    Bansal VV; Belmont E; Godley F; Dhiman A; Witmer HD; Li S; Liao A; Eng OS; Turaga KK; Shergill A
    J Am Coll Surg; 2024 Jun; 238(6):1013-1020. PubMed ID: 38299640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 49. Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.
    Max Ma X; Bendell JC; Hurwitz HI; Ju C; Lee JJ; Lovejoy A; Mancao C; Nicholas A; Price R; Sommer N; Tikoo N; Yao L; Yaung SJ; Palma JF
    Clin Cancer Res; 2020 Aug; 26(15):4010-4017. PubMed ID: 32220893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
    Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.
    Thomsen CB; Andersen RF; Lindebjerg J; Hansen TF; Jensen LH; Jakobsen A
    Clin Colorectal Cancer; 2019 Mar; 18(1):28-33.e3. PubMed ID: 30459076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.
    Kim S; Cha Y; Lim Y; Roh H; Kang JK; Lee KH; Kim MJ; Park JW; Ryoo SB; Kim HP; Jeong SY; Park KJ; Han SW; Kim TY
    Int J Cancer; 2023 Aug; 153(3):571-583. PubMed ID: 37194418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
    Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
    JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
    Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
    Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.
    Elez E; Chianese C; Sanz-García E; Martinelli E; Noguerido A; Mancuso FM; Caratù G; Matito J; Grasselli J; Cardone C; Esposito Abate R; Martini G; Santos C; Macarulla T; Argilés G; Capdevila J; Garcia A; Mulet N; Maiello E; Normanno N; Jones F; Tabernero J; Ciardello F; Salazar R; Vivancos A
    Mol Oncol; 2019 Sep; 13(9):1827-1835. PubMed ID: 31322322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.
    Yamauchi M; Urabe Y; Ono A; Miki D; Ochi H; Chayama K
    Int J Cancer; 2018 Apr; 142(7):1418-1426. PubMed ID: 29134647
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
    Sci Rep; 2019 Nov; 9(1):17358. PubMed ID: 31758080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.